Claritas Pharmaceuticals Inc V.CLAS.H

RE:Article from August 2019

[Captainblk]

some of the things that popped out to me in this article which carry some "meat" in todays terms:
Now, to be fair, the company views diluting shareholders to death as a necessary evil because there is something worth saving here in the best case scenario, possibly even on the level of Epidiolex.
(Epidiolex is a (GW Pharm) brand-name prescription drug. It's used to treat seizures caused by two forms of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. These rare but severe conditions usually appear in early childhood or infancy. Epidiolex contains the drug cannabidiol)
The Phase 3 study will take a year to complete and cost a little less than the Phase 2 trial as the company is homing in on the medium dose. These results got a reaction from analyst Douglas Loe at Echelon Wealth Partners, the agent for the April financing, who said: We believe Kalytera qualifies by both measures and our model assumes that the firm can benefit from economics ascribed to future cash-contributing partners, partners that we are optimistic could be identified prior to commencing Phase III GvHD testing. Our optimism on this theme is clearly enhanced by Phase II data quality as described above.
The other factor looming large in all this is GW Pharmaceuticals. Kalytera and the maker of Epidiolex share the expertise of a key individual, Professor Raphael Mechoulam, head of the Medicinal Chemistry Lab at The Hebrew University of Jerusalem. The Israeli CBD scientist is an advisor in various capacities for both companies, and some in the industry have posited that Mechoulam could broker a deal for GW Pharmaceuticals to scoop up Kalytera and its GvHD drug
I am surprised I haven't read this article before, it highlights some pretty juicy details which add to my own personal confidence. thanks for sharing and GLTA